Great series of works on testing whether this #platform could be used to combine #binding to a #cancer #antigen with engaging both #CD3 and the co-stimulatory receptor #CD28 on T cells https://t.co/dSVROCB9dg #Immunotherapy #Immunology #TCell @nature #N
RT @NatRevImmunol: Cancer immunotherapy goes trispecific https://t.co/2ZQtDdbtve
RT @NatRevImmunol: Cancer immunotherapy goes trispecific https://t.co/2ZQtDdbtve
RT @NatRevImmunol: Cancer immunotherapy goes trispecific https://t.co/2ZQtDdbtve
RT @NatRevImmunol: Cancer immunotherapy goes trispecific https://t.co/2ZQtDdbtve
RT @NatRevImmunol: Cancer immunotherapy goes trispecific https://t.co/2ZQtDdbtve
RT @NatRevImmunol: Cancer immunotherapy goes trispecific https://t.co/2ZQtDdbtve
RT @NatRevImmunol: Cancer immunotherapy goes trispecific https://t.co/2ZQtDdbtve
RT @NatRevImmunol: Cancer immunotherapy goes trispecific https://t.co/2ZQtDdbtve
RT @NatRevImmunol: Cancer immunotherapy goes trispecific https://t.co/2ZQtDdbtve
Cancer immunotherapy goes trispecific https://t.co/2ZQtDdbtve